Use of picoplatin and bevacizumab to treat colorectal cancer

A - Human Necessities – 61 – K

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

A61K 39/395 (2006.01) A61K 31/513 (2006.01) A61K 31/519 (2006.01) A61K 33/24 (2006.01) A61P 35/00 (2006.01) A61P 35/04 (2006.01)

Patent

CA 2715348

The invention provides a method of treatment of metastatic colorectal cancer by administration of the anti-cancer platinum drug picoplatin in conjunction with bevacizumab (Avastin®) and optionally, with 5-FU and leucovorin in a variety of treatment regimens. The invention also provides a use of picoplatin in conjunction with bevacizumab and, optionally, 5-FU and leucovorin, for the treatment of metastatic colorectal cancer.

L'invention porte sur un procédé de traitement d'un cancer colorectal métastatique par administration de picoplatine, médicament anti-cancereux à base de platine, conjointement à du bévacizumab (Avastin®) et facultativement, à du 5-FU et de la leucovorinem, dans une variété de régimes de traitement. L'invention porte également sur lutilisation du picoplatine conjointement à du bévacizumab et, facultativement, à du 5-FU et la leucovorine, pour le traitement d'un cancer colorectal métastatique.

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

Use of picoplatin and bevacizumab to treat colorectal cancer does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Use of picoplatin and bevacizumab to treat colorectal cancer, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of picoplatin and bevacizumab to treat colorectal cancer will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-1828356

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.